BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30946933)

  • 1. The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.
    Dogan S; Ng CKY; Xu B; Kumar R; Wang L; Edelweiss M; Scott SN; Zehir A; Drilon A; Morris LGT; Lee NY; Antonescu CR; Ho AL; Katabi N; Berger MF; Reis-Filho JS
    Hum Pathol; 2019 Jun; 88():66-77. PubMed ID: 30946933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
    Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
    Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
    Chiosea SI; Thompson LD; Weinreb I; Bauman JE; Mahaffey AM; Miller C; Ferris RL; Gooding WE
    Cancer; 2016 Oct; 122(20):3136-3144. PubMed ID: 27379604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review.
    Agaimy A; Baněčková M; Ihrler S; Mueller SK; Franchi A; Hartmann A; Stoehr R; Skálová A
    Am J Surg Pathol; 2021 Sep; 45(9):1166-1178. PubMed ID: 33871952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions.
    Bahrami A; Perez-Ordonez B; Dalton JD; Weinreb I
    Histopathology; 2013 Aug; 63(2):250-62. PubMed ID: 23738717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
    Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
    Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK alterations in salivary gland carcinomas.
    Majewska H; Gorczyński A; Czapiewski P; Menon R; Mueller J; Lakis S; Heuckmann JM; Laco J; Gupta R; Andreasen S; Stodulski D; Iliszko M; Dziadziuszko R; Jassem J; Heukamp LC; Biernat W
    Virchows Arch; 2021 May; 478(5):933-941. PubMed ID: 33237469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of apocrine salivary duct carcinoma.
    Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
    Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
    Nardi V; Sadow PM; Juric D; Zhao D; Cosper AK; Bergethon K; Scialabba VL; Batten JM; Borger DR; Iafrate AJ; Heist RS; Lawrence DP; Flaherty KT; Bendell JC; Deschler D; Li Y; Wirth LJ; Dias-Santagata D
    Clin Cancer Res; 2013 Jan; 19(2):480-90. PubMed ID: 23186780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness.
    Sugano S; Mukai K; Tsuda H; Hirohashi S; Furuya S; Shimosato Y; Ebihara S; Takeyama I
    Laryngoscope; 1992 Aug; 102(8):923-7. PubMed ID: 1353853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
    Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
    Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of TRKB tyrosine kinase in the two histological types of parotid salivary duct carcinoma with cancer aggressiveness.
    Moriwaki K; Ayani Y; Kuwabara H; Terada T; Higashino M; Kawata R
    Oral Oncol; 2024 Apr; 151():106751. PubMed ID: 38479153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
    Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
    Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
    Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
    Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative genomic analysis of salivary duct carcinoma.
    Kim Y; Song S; Lee M; Swatloski T; Kang JH; Ko YH; Park WY; Jeong HS; Park K
    Sci Rep; 2020 Sep; 10(1):14995. PubMed ID: 32929114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of mammaglobin in salivary duct carcinomas de novo and salivary duct carcinoma ex pleomorphic adenoma.
    Soares CD; de Lima Morais TM; Carlos R; Martins MD; de Almeida OP; Mariano FV; Altemani A
    Hum Pathol; 2019 Oct; 92():59-66. PubMed ID: 31400353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutations and PTEN loss in salivary duct carcinomas.
    Griffith CC; Seethala RR; Luvison A; Miller M; Chiosea SI
    Am J Surg Pathol; 2013 Aug; 37(8):1201-7. PubMed ID: 23851329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological study of intraductal carcinoma of the salivary gland, with emphasis on the apocrine type.
    Hsieh MS; Lee YH; Jin YT; Kuo YJ
    Virchows Arch; 2020 Oct; 477(4):581-592. PubMed ID: 32383006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.